<![CDATA[Teclistamab Vs Talquetamab After Relapse on CAR T-Cell Therapy in Multiple Myeloma]]>

Summary

Dr. Ralph V. Boccia discussed clinical considerations for choosing between bispecific antibodies teclistamab and talquetamab in multiple myeloma patients who have relapsed after CAR T-cell therapy, focusing on timing and toxicity profiles.